- Home
- CSTL vs IIIV Comparison
CSTL vs IIIV Comparison
Compare CSTL & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- IIIV
- Stock Information
- Founded
- CSTL 2007
- IIIV 2012
- Country
- CSTL United States
- IIIV United States
- Employees
- CSTL N/A
- IIIV N/A
- Industry
- CSTL Medical Specialities
- IIIV EDP Services
- Sector
- CSTL Health Care
- IIIV Technology
- Exchange
- CSTL Nasdaq
- IIIV Nasdaq
- Market Cap
- CSTL 558.7M
- IIIV 589.9M
- IPO Year
- CSTL 2019
- IIIV 2018
- Fundamental
- Price
- CSTL $16.75
- IIIV $26.20
- Analyst Decision
- CSTL Strong Buy
- IIIV Buy
- Analyst Count
- CSTL 6
- IIIV 7
- Target Price
- CSTL $38.33
- IIIV $29.57
- AVG Volume (30 Days)
- CSTL 548.5K
- IIIV 277.7K
- Earning Date
- CSTL 05-05-2025
- IIIV 05-08-2025
- Dividend Yield
- CSTL N/A
- IIIV N/A
- EPS Growth
- CSTL N/A
- IIIV 4907.14
- EPS
- CSTL N/A
- IIIV 4.75
- Revenue
- CSTL $347,083,000.00
- IIIV $241,651,000.00
- Revenue This Year
- CSTL N/A
- IIIV $10.25
- Revenue Next Year
- CSTL $1.80
- IIIV $12.64
- P/E Ratio
- CSTL N/A
- IIIV $7.66
- Revenue Growth
- CSTL 38.43
- IIIV 5.59
- 52 Week Low
- CSTL $15.70
- IIIV $18.75
- 52 Week High
- CSTL $35.84
- IIIV $29.80
- Technical
- Relative Strength Index (RSI)
- CSTL 34.74
- IIIV 55.21
- Support Level
- CSTL $15.84
- IIIV $24.30
- Resistance Level
- CSTL $17.49
- IIIV $26.95
- Average True Range (ATR)
- CSTL 0.90
- IIIV 1.10
- MACD
- CSTL -0.18
- IIIV 0.05
- Stochastic Oscillator
- CSTL 22.73
- IIIV 75.85
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.